Vascular Disease in Young Indians (20-40 years): Role of Dyslipidemia

Dalal, Jamshed; Deb, Pradeep Kumar; Shrivastava, Sameer; Rao, M. Srinivasa; Mohan, Jagdish C.; Kumar, Arramraju Sreenivas

doi:10.7860/jcdr/2016/18683.8191

Cited by 3 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence from studies that included adult Indian population demonstrated corroborating observations thereby suggesting low HDL-C and hypertriglyceridemia are the two most prevalent clinical manifestations of dyslipidaemia in young as well as adult Indians. [ 2 8 9 14 ] In parallel to these studies, the present study revealed significantly high median levels of TC, TG, LDL-C, and lower HDL-C in the youngest age group (18-25 years) compared to the older age groups in the study. The youngest age group had higher prevalence of hypertriglyceridemia, high LDL-C levels, and low HDL-C levels, while patients from the age group >25 to ≤35 years had the highest incidence of hypercholesterolemia.…”

Section: Discussionsupporting

confidence: 80%

“…Current evidence highlights the grave status quo of the alarming rise in the prevalence of lipid abnormalities in the Indian population aged ≤45 years. [ 14 ] The major attributable risk factors include a sedentary lifestyle, lack of physical activity, increased intake of junk food, smoking/tobacco use, alcohol consumption, mental stress, etc., However, there is a lot of variation in the reported prevalence of dyslipidaemia in young Indians with a higher proportion of affected men. [ 2 7 8 9 15 17 18 ]…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Risk factors, comorbiditiEs and Atherogenic dysLipidaemia in Indian YOUNG patients with dyslipidaemia attending hospital/clinic: REAL YOUNG (dyslipidaemia) study

Iyengar

Narasingan

Gandhi³

et al. 2020

J Family Med Prim Care

View full text Add to dashboard Cite

Objective: To evaluate the pattern of dyslipidaemia, risk factors, and comorbidities in young Indian adults with dyslipidaemia. Methods: A retrospective, multi-centric real-world study included individuals with dyslipidaemia, aged 18 - 45 years, attending to 623 hospitals/clinics across India. Data were collected retrospectively from medical records to note demographics, risk factors (smoking, alcohol consumption, sedentary lifestyle, family history of dyslipidaemia, diabetes mellitus, and hypertension), and clinical details (height, weight, waist circumference, body mass index (BMI), blood pressure, blood sugar, glycated hemoglobin (HbA1c), triglycerides (TG), total cholesterol (TC), low-density lipoproteins (LDL-C), and high-density lipoprotein (HDL-C)).A descriptive analysis and comparative analysis (Mann-Whitney U test and Chi-square test) were done. Results: Of the total 8135 patients, the majority were men (65.0%). Overall, 87.1% of population had one or multiple comorbidities which included the presence of dyslipidaemia alone (12.9%), dyslipidaemia with diabetes and hypertension (39.1%), dyslipidaemia with diabetes (33.6%), and dyslipidaemia with hypertension (14.4%). Sedentary lifestyle was prevalent observation in >50% of the population. Youngest age (18 - 25) group had higher prevalence of hypertriglyceridemia (63.2%), high LDL-C levels (56.8%), and low HDL-C levels (64.6%), while patients from the age group >25 to ≤35 years had the highest incidence of hypercholesterolemia (66.6%). Atherogenic dyslipidaemia was observed in 41.9%, 25.5%, and 23.2% of patients from age groups of ≥18 to ≤25, >25 to ≤35, and >35 to ≤45 years, respectively. Patients with HbA1c ≥6.5% had significantly higher levels of TG, TC, LDL-C, and lower HDL-C compared to those with HbA1c <6.5%. Conclusion: Hypertriglyceridemia, high LDL-C, low HDL-C, and atherogenic dyslipidaemia were prevalent in the young Indian cohort and sedentary lifestyle, and HbA1c ≥ 6.5% were the predominant risk factors of dyslipidaemia.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Risk factors, comorbiditiEs and Atherogenic dysLipidaemia in Indian YOUNG patients with dyslipidaemia attending hospital/clinic: REAL YOUNG (dyslipidaemia) study

Iyengar

Narasingan

Gandhi³

et al. 2020

J Family Med Prim Care

View full text Add to dashboard Cite

show abstract

“…Another real-world study from India also provided corroborating evidence that included young adult patients with dyslipidemia and reported the highest prevalence of atherogenic dyslipidemia among the youngest individuals (≥18 to ≤25 years) than individuals from the 25-45 years of age group [ 19 ]. However, in patients with LDL cholesterol < 190 mg/dL, an individual’s 10-year ASCVD risk needs to be considered to deciding on statin therapy [ 20 ]. The Indian study that evaluated the use of glimepiride and metformin combination to control type 2 diabetes mellitus in Indian patients reported concomitant use of statin to manage dyslipidemia [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

“…rosuvastatin treatment across all the four doses(5,10,20, and 40 mg) (p<0.05). Rosuvastatin at 10 mg (40.3 vs 42.8 mg/dL; p<0.0001) and 20 mg (40.4 vs. 44.4 mg/dL; p=0.044) doses were effective in significantly increasing HDL cholesterol levels from pre-treatment.…”

mentioning

confidence: 94%

Real-World Clinical Experience of Rosuvastatin as a Lipid-Lowering Therapy for Primary and Secondary Prevention of Cardiovascular Events (REAL ROSE)

Mehta¹,

Jain²,

Patil³

et al. 2022

Cureus

View full text Add to dashboard Cite

BackgroundRosuvastatin effectively reduces endogenous cholesterol synthesis and low-density lipoprotein (LDL) cholesterol and increases high-density lipoprotein (HDL) cholesterol. This study aimed to evaluate the clinical characteristics of patients and treatment patterns of rosuvastatin as a lipid-lowering therapy for primary and secondary prevention of cardiovascular events in Indian settings. MethodsThis real-world, retrospective multi-centric observational study included patients aged >18 years who received treatment with a rosuvastatin/rosuvastatin-based combination. Demographic and data about concomitant diseases and medications were recorded. ResultsOut of 1,816 patients, the majority were men (66.2%); the mean age was 54.1 years. The patients prescribed rosuvastatin for primary and secondary prevention of cardiovascular events were 71.9% and 28.1%, respectively. Rosuvastatin 10 mg (56.8%) was the most commonly prescribed dose. For primary prevention, 10 mg (65.0%) was the most preferred dose, and for secondary prevention, 20 mg (54.3%) was the most preferred dose. Rosuvastatin treatment significantly (pre-vs. post-treatment) reduced the levels of total cholesterol (227.2 vs. 178.4 mg/dL), triglycerides (212.6 vs. 154.4 mg/dL), and LDL cholesterol (167.0 vs. 125.6 mg/dL), and increased HDL cholesterol levels (40.7 vs. 44.3 mg/dL) (p<0.0001). A total of 1,196 patients received combination therapy with rosuvastatin (aspirin, 34.0%, and fenofibrate, 21.9%). Adverse events were reported in 0.4% of the study population (leg pain, nausea, muscle cramps/pain, bleeding, and myalgia). ConclusionThis study demonstrated the clinical effectiveness and safety of moderate-to high-intensity rosuvastatin (5-40 mg) for primary and secondary prevention of cardiovascular events in the Indian population. A primary prevention strategy with statins can reduce cardiovascular events and associated morbidity and mortality.

show abstract

“…In India, the burden of dyslipidemia is substantial. Significant prevalence of reduced high density lipoprotein cholesterol (HDL-C) and raised triglycerides (TGs) characterizes the Indian dyslipidemia 1 . The Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study reported low HDL-C in 72.3% and raised TGs in 29.5% of study population as against raised total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) in only 13.9% and 11.8% respectively of the study population 2 .…”

Section: Introductionmentioning

confidence: 99%

Adaptation of 2016 European Society of Cardiology/European Atherosclerosis Society guideline for lipid management to Indian patients – A consensus document

Ray

Sawhney

Das³

et al. 2018

Indian Heart Journal

View full text Add to dashboard Cite

In the year 2016, European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines provided recommendations on dyslipidemia management. The recommendation from these guidelines are restricted to European subcontinent. To adapt the updated recommendations for Indian subset of dyslipidemia, a panel of experts in management of dyslipidemia provided their expert opinions. This document provides expert consensus on adapting 2016 ESC dyslipidemia guidelines recommendations in Indian setting. The document also discussed India-specific relevant literature to support the consensus opinions provided in management of dyslipidemia.

show abstract

Vascular Disease in Young Indians (20-40 years): Role of Dyslipidemia

Cited by 3 publications

References 33 publications

Risk factors, comorbiditiEs and Atherogenic dysLipidaemia in Indian YOUNG patients with dyslipidaemia attending hospital/clinic: REAL YOUNG (dyslipidaemia) study

Risk factors, comorbiditiEs and Atherogenic dysLipidaemia in Indian YOUNG patients with dyslipidaemia attending hospital/clinic: REAL YOUNG (dyslipidaemia) study

Real-World Clinical Experience of Rosuvastatin as a Lipid-Lowering Therapy for Primary and Secondary Prevention of Cardiovascular Events (REAL ROSE)

Adaptation of 2016 European Society of Cardiology/European Atherosclerosis Society guideline for lipid management to Indian patients – A consensus document

Contact Info

Product

Resources

About